Device/Diagnostics Quarterly Dealmaking Statistics, Q2 2019
A Look At The Financing, M&A And Alliance Activity In April–June 2019
Executive Summary
Device financing totaled $2.3bn for Q2 2019, with the debt category bringing in the most money. Merger and acquisition deals reached an aggregate $9.1bn (a 25% increase from Q1), thanks mostly to 3M’s $6.7bn takeover of Acelity and its KCI subsidiaries. Diagnostics/research financing, which totaled $2.4bn, showed a significant rise from the previous quarter, while diagnostics/research tools M&A values, at $233m, exhibited a steep decline.
You may also be interested in...
Perrigo Remains Committed To Splitting Off Prescription Despite Delay
Perrigo has pushed back plans to split off its Prescription business as part of its transformation into a consumer self-care focused company.
Acutus Completes $170M Financing To Support AcQMap Commercialization
The deal includes $100m in Series D financing and a $70m credit facility to help Acutus market the AcQMap electrophysiology mapping system along with the associated vascular access devices, AcQCross QX, AcQGuide Flex and AcQGuide Mini.
Medtronic And Boston Scientific Finance Saluda's Neuromodulation System
Saluda Medical has secured funds from Medtronic and Boston Scientific to support the development of its spinal cord stimulation system for pain management.